Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Results> SH PHARMA (02607.HK) 1Q26 Attributable Net Profit Up 6.35% YoY
Recommend 2 Positive 1 Negative 0 |
||||
|
||||
|
SH PHARMA (02607.HK) announced that in 1Q26, operating revenue reached RMB75.262 billion, up 6.36% YoY. Among which, pharmaceutical manufacturing sales revenue was RMB6.806 billion, up 15.64% YoY; pharmaceutical distribution sales revenue was RMB68.456 billion, up 5.52% YoY. During the period, net profit attributable to shareholders of the listed company amounted to RMB1.418 billion, up 6.35% YoY. Basic EPS was RMB0.3823. The industrial segment contributed RMB0.66 billion in profit, while the commercial segment contributed RMB0.834 billion. Major associates contributed RMB56 million in profit. After deducting non-recurring gains and losses, attributable net profit was RMB1.238 billion, down 2.02% YoY. During the period, the companys R&D investment totaled RMB0.577 billion, accounting for 8.47% of industrial sales. Of which, R&D expenses were RMB0.468 billion, representing 6.88% of industrial sales. (ss/u) This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. Auto-translated by AI AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
